Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch

Celldex Therapeutics, Inc.

Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.
Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.
Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).
Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.
Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $282 million (effective 2026-04-01).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters
Value: approximately $282 million
Effective: 2026-04-01

Exact text from the filing

On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).

View on SEC.gov

Browse all material agreements →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-038882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.